Health Care/Hospital
Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer
Highlights * United States Food and Drug Administration (U.S. FDA) provided positive feedback on a pivotal Phase III trial for64Cu-SAR-bisPSMA diagnostic in prostate cancer patients with biochemical recurrence (BCR), AMPLIFY. * The positive results of the completed COBRA and PROPELLER trials,...
2024-10-14 21:02
1796
Tsingke Shines at Cell & Gene Therapy International 2024
BEIJING and BOSTON, Oct. 14, 2024 /PRNewswire/ -- Beijing Tsingke Biotech Co., Ltd. recently concluded a successful exhibition at CGTI2024 inBoston. This premier event attracted over 3,200 global attendees, including professionals from the top 20 biopharma companies. Tsingke showcased its innovat...
2024-10-14 20:11
1453
US FDA issues Study May Proceed letter for the Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors, Sponsored by the US National Cancer Institute
TAIPEI and SAN DIEGO, Oct. 14, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that FDA issues Study May Proceed letter for its developing drug Pid...
2024-10-14 19:00
1726
Samsung Biologics launches high-concentration formulation platform to accelerate high-dose drug development
* S-HiConTM is designed to maximize drug delivery and stability through high-concentration formulation * The platform can address challenges associated with viscosity and achieve stable liquid formulation for over 200 mg/mL subcutaneous administration INCHEON, South Korea, Oct. 14, 2024 /PRNe...
2024-10-14 19:00
1612
Baird Medical to Participate in the American Thyroid Association (ATA) Annual Meeting
NEW YORK, Oct. 14, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leading developer and provider of microwave ablation ("MWA") medical devices inChina, which recently expanded into the U.S. market following its U.S. FDA 510(k) clea...
2024-10-14 17:00
971
BioCity will present the late-breaking clinical trial data of its ETA selective antagonist SC0062 at the American Society of Nephrology (ASN) 2024 with simultaneous publication of the trial data in the Journal of the American Society of Nephrology (JASN)
SHANGHAI, Oct. 14, 2024 /PRNewswire/ -- BioCity Biopharma announced that a late-breaking clinical trial abstract of its endothelin receptor type A (ETA) selective antagonist SC0062 has been selected for oral presentation at ASN Kidney Week 2024 which will take place fromOctober 23 to 27 in San Di...
2024-10-14 15:38
1571
21st TAITA Annual Conference Explores Taiwan's AI Era Strategies in the Global Tech Supply Chain
TAIPEI, Oct. 13, 2024 /PRNewswire/ -- The upcoming 21st TAITA-SV Annual Conference, scheduled forSaturday, October 19, 2024, at the Hyatt Regency Hotel inSanta Clara, California, will focus on the theme "Taiwan's Strategic Layout in the AI Era." The conference will explore howTaiwan leverages its...
2024-10-14 10:32
1237
Zhejiang Taimei Medical Technology Co., Ltd. Is Now Listed on HKEX
HONG KONG, Oct. 13, 2024 /PRNewswire/ -- Zhejiang Taimei Medical Technology Co., Ltd. (the "Company"; Stock code: 2576.HK) has announced that the shares have started to be traded on the Main Board of the Stock Exchange of Hong Kong Limited under the stock code "2576" since today. The Company sai...
2024-10-14 10:18
1253
Modern Meadow Appoints David Williamson as CEO
With his extensive background in material science, biotechnology and production environments,Williamson set to lead company as CEO starting October 14 Modern Meadow continues to build its BIO-VERA® brand and expand production NUTLEY, N.J., Oct. 14, 2024 /PRNewswire/ -- Modern Meadow, a leader in...
2024-10-14 09:00
1108
Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline
Expediting International Clinical Trials for Pivotal Products Key Participants Include International Long-Term and Healthcare Funds HONG KONG, Oct. 13, 2024 /PRNewswire/ -- Akeso Biopharma (9926. HK) ("Akeso", the "Company" ) announced that it has successfully raised approximately$250 million US...
2024-10-13 20:27
3395
Sunvozertinib Granted Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Fourth Breakthrough Therapy Designation for sunvozertinib in NSCLC with EGFR exon20ins SHANGHAI, Oct. 13, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the Center...
2024-10-13 16:04
2111
Ailux Biologics, a Division of XtalPi, Enters into a License Agreement with Janssen Biotech on Biologics AI Platform
CAMBRIDGE, Mass., Oct. 12, 2024 /PRNewswire/ -- XtalPi, a global leader in AI drug discovery, announced today a license agreement between Ailux Biologics, a division of XtalPi Inc., and Janssen Biotech, Inc.,(Janssen) a Johnson & Johnson company, on one of its proprietary biologics AI platforms. ...
2024-10-12 16:57
4098
X3 Holdings Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Requirement
SINGAPORE, Oct. 11, 2024 /PRNewswire/ -- X3 Holdings Co., Ltd. (Nasdaq: XTKG) (the "Company" or "XTKG"), a global provider of digital solutions and technology services spanning diverse industries, today announced that it has received an extension of 180 calendar days from the Listing Qualificatio...
2024-10-12 04:30
5358
Baird Medical Announces Preliminary Financial Results for the Six Months Ended June 30, 2024
Total revenues increased to US$13.1 million, representing 13.8% year-over-year growth Net income reached US$4.4 million, representing 85.8% year-over-year growth GUANGZHOU, China, Oct. 11, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"...
2024-10-11 20:00
4440
GenScript Biotech Advances Sustainable Development with MSCI ESG Rating Upgrade to A
PISCATAWAY, N.J., Oct. 11, 2024 /PRNewswire/ -- GenScript Biotech Corporation has recently been upgraded to an A rating in its Environmental, Social, and Governance (ESG) score by MSCI, a globally recognized rating agency. This upgrade reflects GenScript's unwavering commitment to integrating su...
2024-10-11 17:09
2452
Waterdrop Inc. Released 2023 ESG Report: Adhere to both Sci-tech Innovation and Social Responsibility
BEIJING, Oct. 11, 2024 /PRNewswire/ -- Waterdrop Inc. released its Environmental, Social and Governance (ESG) Report 2023 ("the Report") in October. The Report details Waterdrop Inc.'s efforts in a number of key areas such as corporate governance, technology and innovation, inclusive protection ...
2024-10-11 12:44
1718
Delegation of International Communication Experts and Foreign Media Outlets Visits Emerging Industry Enterprises in Zhongshan, Guangdong Province
BEIJING, Oct. 10, 2024 /PRNewswire/ -- On October 9, 2024, the delegation of international communication experts and foreign media outlets, themed "The World Comes to Zhongshan" and organized by the CICG Academy of Translation and Interpretation, visited several representative enterprises in Zhon...
2024-10-11 00:53
2056
Datasea Pre-announces Estimated First Quarter 2025 Fiscal Year Revenue of approximately $22.7 Million, Up 230% Year-Over-Year
BEIJING, Oct. 10, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), aNevada-registered digital technology company focused on innovations in acoustics high-tech and 5G AI multimodal digital technologies, today pre-announced that its revenue for the first quarter of fis...
2024-10-10 21:45
3510
111 Inc. Expands National Supply Chain Network with New Fulfillment Centers across South and Central China
SHANGHAI, Oct. 10, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that new fulfillme...
2024-10-10 18:02
3482
Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Oct. 9, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunolo...
2024-10-10 11:04
1354
Week's Top Stories
Most Reposted
Mayapada Hospitality Holding Open the first voco Hotel in Indonesia.
[Picked up by 309 media titles]
2024-12-20 16:25
AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
[Picked up by 306 media titles]
2024-12-20 18:11
XTransfer and OCBC Jointly Announce Comprehensive Partnership
[Picked up by 266 media titles]
2024-12-23 17:36
CKGSB Successfully Hosts 2024 MBA Professor Training Program for Western China
[Picked up by 252 media titles]
2024-12-24 00:06ebm-papst A&NZ Achieves Complete Operational Carbon Neutrality in appropriate Scope 1,2 and 3 criterion in 2023
[Picked up by 244 media titles]
2024-12-25 15:45Most Read
AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
2024-12-20 18:11
12177
Mayapada Hospitality Holding Open the first voco Hotel in Indonesia.
2024-12-20 16:25
7143